评估StrataGraft®用于深二度热烧伤患者的STRATA2011与STRATA2016临床试验汇总安全性分析
本文汇总了2项临床试验(NCT01437852;NCT03005106)中StrataGraft治疗深二度烧伤的安全性数据,共纳入101例成人热烧伤患者,随访长达1年。结果显示86.1%患者发生不良事件,最常见为瘙痒(30.7%),29.7%发生不良反应,15.8%发生严重不良事件;StrataGraft耐受性良好,安全性特征与自体皮片相似,可能为深二度烧伤提供安全的自体皮片替代选择。
要点
- StrataGraft在深二度热烧伤患者中耐受性良好,安全性特征与自体皮片相似。
- 最常见不良事件为瘙痒(30.7%),最常见不良反应亦为瘙痒(12.9%)。
- 3个月时群体反应性抗体及HLA等位基因反应性≤25%,无StrataGraft同种异体DNA持续存在。
核心结论
- StrataGraft耐受性良好,安全性特征与自体皮片相似,可能为深二度烧伤提供安全的自体皮片替代选择。
研究设计与样本
- 汇总2项临床试验(NCT01437852;NCT03005106)的安全性数据,纳入101例热烧伤面积占总体表面积3-49%的成人患者,随访长达1年。
主要发现
- 87例(86.1%)患者发生397例次不良事件,30例(29.7%)发生不良反应,16例(15.8%)发生严重不良事件。
- 最常见不良事件为瘙痒(n=31;30.7%),其次为大疱、高血压和增生性瘢痕(各n=11;10.9%);最常见不良反应为瘙痒(n=13;12.9%)。
- 1例患者退出研究;2例患者发生与StrataGraft无关的严重不良事件导致死亡。
- 第3个月时群体反应性抗体和HLA等位基因反应性≤25%,无StrataGraft同种异体DNA持续存在。
临床怎么用
- 原文结论指出StrataGraft可能为深二度烧伤提供安全的自体皮片替代选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This analysis includes pooled safety data from 2 clinical trials (NCT01437852; NCT03005106) that evaluated the safety and efficacy of StrataGraft in patients with deep partial-thickness (DPT) burns. METHODS: The study enrolled 101 adult patients with thermal burns covering 3-49% of total body surface area. Patients were followed for up to 1 year. The pooled safety events included: adverse events (AEs), adverse reactions (ARs), serious AEs (SAEs), discontinuation, and deaths; immunological responses (reactivity to panel reactive antibodies [PRA] and human leukocyte antigen [HLA] class 1 alleles); and persistence of allogeneic DNA from StrataGraft. RESULTS: Eighty-seven (86.1%) patients experienced 397 AEs. Thirty patients (29.7%) experienced ARs; 16 patients (15.8%) experienced SAEs. The most frequent AEs were pruritus (n = 31; 30.7%), and blister, hypertension, and hypertrophic scar (n = 11 each; 10.9%); the most common AR was pruritus (n = 13; 12.9%). One patient discontinued the study; 2 patients experienced SAEs (unrelated to StrataGraft) leading to death. PRA and HLA allele reactivity was ≤ 25% at Month 3, with no persistent allogeneic DNA from StrataGraft. CONCLUSIONS: StrataGraft was well tolerated by patients, with a safety profile similar to autograft. StrataGraft may offer a safe alternative to autograft for DPT burns.
引用
- Holmes Iv JH, Cancio LC, Carter JE, et al. Pooled safety analysis of STRATA2011 and STRATA2016 clinical trials evaluating the use of StrataGraft® in patients with deep partial-thickness thermal burns. Burns. 2022. PMID: 35941023. doi:10.1016/j.burns.2022.07.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。